» Articles » PMID: 35317548

Therapeutic Strategies for Gastroenteropancreatic Neuroendocrine Neoplasms: State-of-the-art and Future Perspectives

Abstract

Although gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have always been considered rare tumors, their incidence has risen over the past few decades. They represent a highly heterogeneous group of neoplasms with several prognostic factors, including disease stage, proliferative index (Ki67), and tumor differentiation. Most of these neoplasms express somatostatin receptors on the cell surface, a feature that has important implications in terms of prognosis, diagnosis, and therapy. Although International Guidelines propose algorithms aimed at guiding therapeutic strategies, GEP-NEN patients are still very different from one another, and the need for personalized treatment continues to increase. Radical surgery is always the best option when feasible; however, up to 80% of cases are metastatic upon diagnosis. Regarding medical treatments, as GEP-NENs are characterized by relatively long overall survival, multiple therapy lines are adopted during the lifetime of these patients, but the optimum sequence to be followed has never been clearly defined. Furthermore, although new molecular markers aimed at predicting the response to therapy, as well as prognostic scores, are currently being studied, their application is still far from being part of daily clinical practice. As they represent a complex disease, with therapeutic protocols that are not completely standardized, GEP-NENs require a multidisciplinary approach. This review will provide an overview of the available therapeutic options for GEP-NENs and attempts to clarify the possible approaches for the management of these patients and to discuss future perspectives in this field.

Citing Articles

Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.

Criss C, Makary M Curr Oncol. 2024; 31(4):2076-2091.

PMID: 38668057 PMC: 11049250. DOI: 10.3390/curroncol31040154.

References
1.
Cives M, Pelle E, Quaresmini D, Rizzo F, Tucci M, Silvestris F . The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology. 2019; 109(2):83-99. DOI: 10.1159/000497355. View

2.
Dong D, Zhang X, Poultsides G, Rocha F, Weber S, Fields R . Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases. J Surg Oncol. 2019; 120(7):1071-1079. PMC: 10178766. DOI: 10.1002/jso.25716. View

3.
Lu Y, Zhao Z, Wang J, Lv W, Lu L, Fu W . Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis. Medicine (Baltimore). 2018; 97(41):e12784. PMC: 6203503. DOI: 10.1097/MD.0000000000012784. View

4.
Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E, Kolasinska-Cwikla A . Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?. Oncologist. 2020; 26(4):294-301. PMC: 8018333. DOI: 10.1002/onco.13633. View

5.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View